drugset / Trial / NCT04970355

Efficacy of Erenumab in Chronic Cluster Headache

NCT04970355

Phase 2 Completed 101 enrolled Charite University, Berlin, Germany
RandomizedParallel-groupDouble-blindPrevention

Summary

The main purpose of this study is to evaluate the efficacy of erenumab in participants with chronic cluster headache.

Timeline

Start
2021-12-02
Primary completion
2023-09-27
Completion
2023-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody 140 mg Subcutaneous